Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tailored-Dose Docetaxel + Trastuzumab in HER2+ Metastatic Breast Cancer
NCT00146042Phase 2Completed
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Mar 1999
- Primary completion
- Mar 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel in breast cancer, sponsored by University of Michigan Rogel Cancer Center. Primary endpoint: Variability in drug area under the curve (AUC) at 2 months. Started Mar 1999; status: completed.
02
Drugs
docetaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00146042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00146042.